Literature DB >> 25483648

Live attenuated pre-erythrocytic malaria vaccines.

Gladys J Keitany1, Marissa Vignali, Ruobing Wang.   

Abstract

Although recent control measures have significantly reduced malaria cases and deaths in many endemic areas, an effective vaccine will be essential to eradicate this parasitic disease. Malaria vaccine strategies developed to date focus on different phases of the parasite's complex life cycle in the human host and mosquito vector, and include both subunit-based and whole-parasite vaccines. This review focuses on the 3 live-attenuated malaria vaccination strategies that have been tested in humans to date, and discusses their progress, challenges and the immune correlates of protection that have been identified.

Entities:  

Keywords:  CPS, Chemoprophylaxis and Sporozoite immunization; CQ, chloroquine; CSP, circumsporozoite protein; GAP, Genetically Attenuated Parasite; ITV, Immunization-Treatment-Vaccination; Malaria; P. falciparum; PfSPZ, P. falciparum sporozoite vaccine; RAS, Radiation Attenuated Sporozoites; attenuation; i.d., intradermal; i.v., intravenous; pre-erythrocytic; s.c., subcutaneous; whole-parasite vaccines

Mesh：

Substances：

Year:  2014        PMID： 25483648      PMCID： PMC5443077          DOI： 10.4161/21645515.2014.972764

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  78 in total

1.  Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challenge.

Authors:  R Harpaz; R Edelman; S S Wasserman; M M Levine; J R Davis; M B Sztein
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

2.  Induction of antimalaria immunity by pyrimethamine prophylaxis during exposure to sporozoites is curtailed by parasite resistance.

Authors:  Johannes Friesen; Steffen Borrmann; Kai Matuschewski
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

3.  Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen.

Authors:  R L Beaudoin; C P Strome; F Mitchell; T A Tubergen
Journal:  Exp Parasitol       Date:  1977-06       Impact factor: 2.011

4.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

Authors:  K A Bojang; P J Milligan; M Pinder; L Vigneron; A Alloueche; K E Kester; W R Ballou; D J Conway; W H Reece; P Gothard; L Yamuah; M Delchambre; G Voss; B M Greenwood; A Hill; K P McAdam; N Tornieporth; J D Cohen; T Doherty
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

5.  Genetically modified Plasmodium parasites as a protective experimental malaria vaccine.

Authors:  Ann-Kristin Mueller; Mehdi Labaied; Stefan H I Kappe; Kai Matuschewski
Journal:  Nature       Date:  2004-12-05       Impact factor: 49.962

6.  Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface.

Authors:  Ann-Kristin Mueller; Nelly Camargo; Karine Kaiser; Cathy Andorfer; Ute Frevert; Kai Matuschewski; Stefan H I Kappe
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

7.  In vivo imaging of CD8+ T cell-mediated elimination of malaria liver stages.

Authors:  Ian A Cockburn; Rogerio Amino; Reka K Kelemen; Scot C Kuo; Sze-Wah Tse; Andrea Radtke; Laura Mac-Daniel; Vitaly V Ganusov; Fidel Zavala; Robert Ménard
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-14       Impact factor: 11.205

8.  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; José Francisco Fernandes; Béatrice Peggy Abossolo; Barbara Gaelle Nfono Ondo Methogo; Anita Lumeka Kabwende; Ayola Akim Adegnika; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Sonia Machevo; Sozinho Acacio; Helder Bulo; Betuel Sigauque; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Rose Minja; Maxmillian Mpina; Saumu Ahmed; Ali Mohammed Ali; Ali Takadir Mtoro; Ali Said Hamad; Paul Mutani; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Biébo Bihoun; Issa Guiraud; Berenger Kaboré; Olivier Sombié; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Martina Oneko; Chris Odero; Kephas Otieno; Norbert Awino; Meredith McMorrow; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Nekoye Otsyula; Stacey Gondi; Allan Otieno; Victorine Owira; Esther Oguk; George Odongo; Jon Ben Woods; Bernhards Ogutu; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Charity Maingi; Trudie Lang; Ally Olotu; Philip Bejon; Kevin Marsh; Gabriel Mwambingu; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; David Dosoo; Isaac Asante; George Adjei; Evans Kwara; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Coline Mahende; Edwin Liheluka; Lincoln Malle; Martha Lemnge; Thor G Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Anima Sarfo; Alex Agyekum; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Rutendo Nkomo; Tapiwa Tembo; Gerald Tegha; Mercy Tsidya; Jane Kilembe; Chimwemwe Chawinga; W Ripley Ballou; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Aurélie Olivier; Johan Vekemans; Terrell Carter; David Kaslow; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2012-11-09       Impact factor: 91.245

9.  The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection.

Authors:  Michael T White; Philip Bejon; Ally Olotu; Jamie T Griffin; Eleanor M Riley; Kent E Kester; Christian F Ockenhouse; Azra C Ghani
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

Review 10.  CD8 T-cell-mediated protection against liver-stage malaria: lessons from a mouse model.

Authors:  Natalija Van Braeckel-Budimir; John T Harty
Journal:  Front Microbiol       Date:  2014-06-06       Impact factor: 5.640
View more
  5 in total

Review 1.  An expanding toolkit for preclinical pre-erythrocytic malaria vaccine development: bridging traditional mouse malaria models and human trials.

Authors:  Ryan Wj Steel; Stefan Hi Kappe; Brandon K Sack
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

2.  Chemoprophylaxis under sporozoites-lumefantrine (CPS-LMF) immunization induce protective immune responses against Plasmodium yoelii sporozoites infection in mice.

Authors:  Arif Jamal Siddiqui; Jyoti Bhardwaj; Walid Sabri Hamadou; Manish Goyal; Syed Amir Ashraf; Sadaf Jahan; Arshad Jamal; Pankaj Sharma; Manojkumar Sachidanandan; Riadh Badraoui; Mohd Adnan
Journal:  3 Biotech       Date:  2021-10-19       Impact factor: 2.406

3.  Blood Stage Plasmodium falciparum Exhibits Biological Responses to Direct Current Electric Fields.

Authors:  Lorena M Coronado; Stephania Montealegre; Zumara Chaverra; Luis Mojica; Carlos Espinosa; Alejandro Almanza; Ricardo Correa; José A Stoute; Rolando A Gittens; Carmenza Spadafora
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

4.  Conditional knockout tools: Application of site-specific incorporation of unnatural amino acid via genetic code expansion in viral and parasite vaccine development.

Authors:  Pinghua Liu; Lubin Jiang
Journal:  Synth Syst Biotechnol       Date:  2017-03-11

5.  Killing the competition: a theoretical framework for liver-stage malaria.

Authors:  Clemente F Arias; Francisco J Acosta; Cristina Fernandez-Arias
Journal:  Open Biol       Date:  2022-03-30       Impact factor: 6.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.